{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:38:06Z","timestamp":1775885886269,"version":"3.50.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Fosfomycin is gaining increasing attention for its activity against MDR or XDR pathogens. Currently, IV fosfomycin is a potential option for treating various infections, including urinary tract infections, pneumonia and skin infections when first-line treatments fail.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the demographic, clinical, microbiological and treatment modality of children received IV fosfomycin to treat infections caused by MDR pathogens since there are few data on the use of fosfomycin in children.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study was conducted retrospectively with patients under 18 years of age who were treated with IV fosfomycin for at least 72 h due to infections caused by MDR pathogens between January 2019 and October 2023 at Marmara University Pendik Training and Research Hospital, \u0130stanbul, T\u00fcrkiye. Data on demographic and clinical features, microbiological findings, treatment modalities and side effects were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-five children, for a total of 32 cases of infection episodes, with a mean age of 11.4\u200a\u00b1\u200a3.92 years who received IV fosfomycin were included. The most frequent comorbidity was chronic pulmonary diseases, and the most common infection needed for IV fosfomycin was MDR Pseudomonas aeruginosa pneumonia. In all cases, fosfomycin was administered in combination with other antibiotics, mainly meropenem\u2013colistin (68.7%) or meropenem (15.6%). Twenty-two (71.9%) cases had favourable clinical responses at the end of therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results suggest that IV fosfomycin may be an effective treatment option for MDR pathogens in the paediatric population. Nevertheless, careful stewardship is necessary to maintain efficacy and reduce antimicrobial resistance selection risk.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae204","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T11:22:02Z","timestamp":1720869722000},"page":"2179-2185","source":"Crossref","is-referenced-by-count":5,"title":["The use of fosfomycin in infections caused by multidrug-resistant pathogens, especially pneumonia in children: a five-year retrospective single-centre experience"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5420-3706","authenticated-orcid":false,"given":"Aylin","family":"Dizi I\u015f\u0131k","sequence":"first","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine , \u0130stanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1444-1187","authenticated-orcid":false,"given":"G\u00fcl\u015fen","family":"Akko\u00e7","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine , \u0130stanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-6489","authenticated-orcid":false,"given":"Zeynep","family":"Ergen\u00e7","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine , \u0130stanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6873-0745","authenticated-orcid":false,"given":"Seyhan","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine , \u0130stanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2626-0316","authenticated-orcid":false,"given":"Sevgi","family":"Aslan Tuncay","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine , \u0130stanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1222-8761","authenticated-orcid":false,"given":"Burcu","family":"Parlak","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine , \u0130stanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6200-3173","authenticated-orcid":false,"given":"P\u0131nar","family":"Canizci Erdemli","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine , \u0130stanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2267-5271","authenticated-orcid":false,"given":"Didem","family":"B\u00fcy\u00fckta\u015f Ayta\u00e7","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine , \u0130stanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3960-4265","authenticated-orcid":false,"given":"M \u00c7a\u011fla","family":"Abac\u0131 \u00c7apar","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine , \u0130stanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7175-303X","authenticated-orcid":false,"given":"Sevliya","family":"\u00d6cal Demir","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine , \u0130stanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1886-5224","authenticated-orcid":false,"given":"Eda","family":"Kepenekli","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Marmara University School of Medicine , \u0130stanbul , T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,13]]},"reference":[{"key":"2024090302260621700_dkae204-B1","author":"Centers for Disease Control and Prevention","year":"2019"},{"key":"2024090302260621700_dkae204-B2","author":"World Health Organization","year":"2022"},{"key":"2024090302260621700_dkae204-B3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2024090302260621700_dkae204-B4","author":"McDonnell","year":"2022"},{"key":"2024090302260621700_dkae204-B5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2024090302260621700_dkae204-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/jmm.0.001573","article-title":"JMM profile: fosfomycin: a potential antibiotic for multi- and extensively resistant bacteria","volume":"71","author":"Wangchinda","year":"2022","journal-title":"J Med Microbiol"},{"key":"2024090302260621700_dkae204-B7","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024090302260621700_dkae204-B8","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3346\/jkms.2023.38.e361","article-title":"Susceptibility to fosfomycin and nitrofurantoin of ESBL-positive Escherichia coli and Klebsiella pneumoniae isolated from urine of pediatric patients","volume":"38","author":"Park","year":"2023","journal-title":"J Korean Med Sci"},{"key":"2024090302260621700_dkae204-B9","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jac\/dkad131","article-title":"A multicentre, retrospective audit of fosfomycin use for urinary tract infections in Australian children and adolescents","volume":"78","author":"Purcell","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2024090302260621700_dkae204-B10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/INF.0000000000004263","article-title":"Back to the future: intravenous fosfomycin is safe and effective for the treatment of complicated infections in children","volume":"43","author":"Roversi","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"2024090302260621700_dkae204-B11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40121-015-0092-8","article-title":"Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA adverse event reporting system database","volume":"4","author":"Iarikov","year":"2015","journal-title":"Infect Dis Ther"},{"key":"2024090302260621700_dkae204-B12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2024090302260621700_dkae204-B13","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3855\/jidc.14125","article-title":"Retrospective evaluation of intravenous fosfomycin in multi-drug resistant infections at a tertiary care hospital in Lebanon","volume":"15","author":"Ballouz","year":"2021","journal-title":"J Infect Dev Ctries"},{"key":"2024090302260621700_dkae204-B14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/00365548.2011.616221","article-title":"Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria","volume":"44","author":"Dinh","year":"2012","journal-title":"Scand J Infect Dis"},{"issue":"Suppl 1","key":"2024090302260621700_dkae204-B15","first-page":"55","article-title":"Fosfomycin in the pediatric setting: evidence and potential indications","volume":"32","author":"Baquero-Artigao","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"2024090302260621700_dkae204-B16","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/jpc.14883","article-title":"Potential of fosfomycin in treating multidrug-resistant infections in children","volume":"56","author":"Williams","year":"2020","journal-title":"J Paediatr Child Health"},{"key":"2024090302260621700_dkae204-B17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14787210.2021.1932463","article-title":"Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review","volume":"20","author":"Tsegka","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024090302260621700_dkae204-B18","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s40265-017-0745-x","article-title":"The potential role of fosfomycin in neonatal sepsis caused by multidrug-resistant bacteria","volume":"77","author":"Li","year":"2017","journal-title":"Drugs"},{"key":"2024090302260621700_dkae204-B19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.idcr.2014.11.004","article-title":"Favorable outcome in cerebral abscesses caused by Citrobacter koseri in a newborn infant","volume":"2","author":"Algubaisi","year":"2015","journal-title":"IDCases"},{"key":"2024090302260621700_dkae204-B20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","article-title":"Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection","volume":"185","author":"Trapnell","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2024090302260621700_dkae204-B21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmi.2016.12.005","article-title":"Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature","volume":"23","author":"Grabein","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2024090302260621700_dkae204-B22","doi-asserted-by":"crossref","first-page":"e00779-19","DOI":"10.1128\/AAC.00779-19","article-title":"Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa","volume":"63","author":"Mikhail","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024090302260621700_dkae204-B23","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/jac\/dkw115","article-title":"Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance","volume":"71","author":"Walsh","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2024090302260621700_dkae204-B24","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.jiph.2021.09.025","article-title":"Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections","volume":"14","author":"Abdallah","year":"2021","journal-title":"J Infect Public Health"},{"key":"2024090302260621700_dkae204-B25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jac\/dkp224","article-title":"Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model","volume":"64","author":"Cai","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2024090302260621700_dkae204-B26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10096-011-1360-5","article-title":"Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates","volume":"31","author":"Samonis","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024090302260621700_dkae204-B27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1569-1993(02)00143-1","article-title":"Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis","volume":"2","author":"Mirakhur","year":"2003","journal-title":"J Cyst Fibros"},{"key":"2024090302260621700_dkae204-B28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pupt.2018.04.007","article-title":"Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: real life experience of a large adult CF centre","volume":"50","author":"Spoletini","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"2024090302260621700_dkae204-B29","doi-asserted-by":"crossref","first-page":"e0190621","DOI":"10.1128\/spectrum.01906-21","article-title":"Clinical risk factors and microbiological and intestinal characteristics of carbapenemase-producing Enterobacteriaceae colonization and subsequent infection","volume":"10","author":"Yuan","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2024090302260621700_dkae204-B30","doi-asserted-by":"crossref","first-page":"115505","DOI":"10.1016\/j.diagmicrobio.2021.115505","article-title":"Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia","volume":"101","author":"Hovan","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024090302260621700_dkae204-B31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2013.09.010","article-title":"Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria","volume":"43","author":"Pontikis","year":"2014","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/9\/2179\/58998482\/dkae204.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/9\/2179\/58998482\/dkae204.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T02:26:26Z","timestamp":1725330386000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/9\/2179\/7713241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,13]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,13]]},"published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae204","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,13]]}}}